4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet
29
Participants partenaires
TERMINÉ
Profiling Responders In Antibody Therapies (PRIAT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,
...tastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This met ...
Voir le projet
8
Participants partenaires
TERMINÉ
European Consortium for Anticancer Antibody Development (EUCAAD)
Date du début: 1 mai 2008, Date de fin: 30 avr. 2012,
Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. R ...
Voir le projet
9
Participants partenaires
TERMINÉ
ANTIBODY DERIVATIVES AS MOLECULAR AGENTS FOR NEOPLASTIC TARGETING (ADAMANT)
Date du début: 1 avr. 2008, Date de fin: 31 mars 2011,
"The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability. Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can disp ...
Voir le projet